BioSpring hosts event on “Genome Editing – Medicine of the Future” in Frankfurt
Panel discussion at the event. From left to right: Claudia Englbrecht (BIO Deutschland), Toni Cathomen (University Medical Center Freiburg), Jörg Vogel (University of Würzburg), Hüseyin Aygün (BioSpring), Daniela Karlstetter (Bayer), Jochen Maas (House of Pharma). Picture on the right, from left to right: Sylvia Wojczweski (BioSpring), German Research Minister Bettina Stark-Watzinger, Hüseyin Aygün (BioSpring).
On 9th February, BIO Deutschland member BioSpring hosted an event on the topic of “Genome Editing – Medicine of the Future” at the Union Halle in Frankfurt am Main. BioSpring is the global market leader in cGMP manufacturing of guide RNA, which is necessary for genome editing applications such as CRISPR/Cas. German Research Minister Bettina Stark-Watzinger gave a speech in which she emphasised the outstanding importance of developing genome editing therapeutics. Renowned researchers and industry experts delivered exclusive talks to the attendees, who consisted of professionals from life science, business, and politics, offering insights into the groundbreaking advancements that genome editing will bring in the near future. Claudia Englbrecht from BIO Deutschland moderated a panel discussion with scientists and industry representatives on the topic of “The Potential of Genome Editing and Active Ingredients ‘Made in Germany’” which looked at how the framework conditions for R&D and manufacturing in Germany could be improved.